Ranibizumab Approved in EU for Myopia ComplicationRanibizumab Approved in EU for Myopia Complication
A clinical trial has shown that patients with choroidal neovascularization generally experienced better vision after 1 injection of the vascular endothelial growth factor inhibitor. International Approvals (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 5, 2013 Category: Consumer Health News Tags: Ophthalmology News Alert Source Type: news
EU approves Novartis eye drug for new use
ZURICH (Reuters) - Swiss drugmaker Novartis' eye drug Lucentis has been approved as a treatment for a further condition related to worsening eyesight by the European Union, adding to three other conditions for which it is already approved. (Source: Reuters: Health)
Source: Reuters: Health - July 5, 2013 Category: Consumer Health News Tags: healthNews Source Type: news
Pilot Study Has Promising Results For Age-Related Macular Degeneration
There is no cure for age-related macular degeneration, an eye disease that is the leading cause of vision loss and blindness in older Americans. Last year, the National Institutes of Health reported that two drugs injected into the eyes, Avastin and Lucentis, eased symptoms for sufferers, especially those in the advanced, "wet" stage of the disease, when blood vessels in the eye become swollen and leak fluids in the eye. Yet for some AMD patients, the two drugs either don't work for long or fail to work at all. It's a dead end for treatment, or so it seemed... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 21, 2013 Category: Consumer Health News Tags: Eye Health / Blindness Source Type: news
No Proof Of Added Benefit Found For Aflibercept In Wet Age-Related Macular Degeneration
Manufacturer's dossier did not contain any usable data for the comparison with ranibizumab The drug aflibercept (trade name: Eylea) has been approved in Germany since November 2012 for the treatment of wet age-related macular degeneration (AMD). In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG) the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether this new drug offers an added benefit over the current standard therapy... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 7, 2013 Category: Consumer Health News Tags: Eye Health / Blindness Source Type: news
Lucentis® receives positive opinion
Novartis has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for Lucentis® (ranibizumab) to treat patients with visual impairment due to choroidal neovascularisation (CNV) secondary to pathologic myopia (myopic CNV). (Source: Pharmacy Europe)
Source: Pharmacy Europe - June 4, 2013 Category: Drugs & Pharmacology Source Type: news
Bayer’s AMD drug to rival Lucentis after NICE recommendation
The National Institute of Health and Care Excellence in the UK has recommended Bayer's wet age-related macular degeneration (AMD) drug Eylea in its final draft guidance published today. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - May 30, 2013 Category: Pharmaceuticals Source Type: news
RVO: Reading Speed Improves With Ranibizumab Injections RVO: Reading Speed Improves With Ranibizumab Injections
Ranibizumab therapy makes a functional difference for patients with retinal vein occlusion, researchers have found. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 24, 2013 Category: Consumer Health News Tags: Ophthalmology News Source Type: news
Bevacizumab Cheaper Than Ranibizumab for Macular DegenerationBevacizumab Cheaper Than Ranibizumab for Macular Degeneration
Cost analysis favors one vascular endothelial growth factor inhibitor over another for patients with age-related macular degeneration. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 23, 2013 Category: Consumer Health News Tags: Ophthalmology News Source Type: news
Bevacizumab, Ranibizumab Comparable for Macular DegenerationBevacizumab, Ranibizumab Comparable for Macular Degeneration
Investigators report no difference between the 2 agents for visual acuity at 1 year, but concern lingers over adverse events. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 9, 2013 Category: Consumer Health News Tags: Ophthalmology News Source Type: news
Real-world data highlight transformational outcomes seen with Lucentis®
Novartis has reported that new data with the eye drug Lucentis® (ranibizumab), first licensed in June 2006, is highlighted in a total of 209 abstracts at the 2013 Association for Research in Vision and Ophthalmology (ARVO) annual meeting this week. (Source: Pharmacy Europe)
Source: Pharmacy Europe - May 8, 2013 Category: Drugs & Pharmacology Source Type: news
Topol Talks to Ferrara, $3M Breakthrough Prize WinnerTopol Talks to Ferrara, $3M Breakthrough Prize Winner
Dr. Eric Topol talks with Dr. Napoleone Ferrara, recent winner of the Breakthrough Prize in Life Sciences and the researcher whose work led to the synthesis of bevacizumab and ranibizumab. Medscape One-on-One (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - May 2, 2013 Category: Intensive Care Tags: Internal Medicine Expert Interview Source Type: news
Side Effect Of Retinal Detachment May Be Prevented By Ranibizumab
Proliferative vitreoretinopathy (PVR), or the formation of scar tissue in the eye, is a serious, sight-threatening complication in people recovering from surgical repair of retinal detachment. PVR is difficult to predict, lacks effective treatment options, and substantially reduces an individual's quality of life. Each year 55,000 people are at risk for developing PVR in the United States alone... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - April 11, 2013 Category: Consumer Health News Tags: Eye Health / Blindness Source Type: news
Ranibizumab may prevent retinal detachment side effect
(Massachusetts Eye and Ear Infirmary) Proliferative vitreoretinopathy (PVR), or the formation of scar tissue in the eye, is a serious, sight-threatening complication in people recovering from surgical repair of retinal detachment. A new study suggests that Ranibizumab, an anti-VEGF-A monoclonal antibody fragment, is a potential prophylaxis for PVR. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - April 9, 2013 Category: Global & Universal Source Type: news
Ranibizumab or Bevacizumab in Patients With Neovascular AMDRanibizumab or Bevacizumab in Patients With Neovascular AMD
Is there a particular anti-VEGF agent that works best in neovascular AMD? This new study compares ranibizumab and bevacizumab. The British Journal of Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 29, 2013 Category: Consumer Health News Tags: Ophthalmology Journal Article Source Type: news
NCI Grantees Receive Breakthrough Prizes in Life Sciences
The Breakthrough Prize in Life Sciences recognizes “excellence in research aimed at curing intractable diseases and extending human life.” The inaugural set of prizes, awarded in February 2013 by a not-for-profit corporation dedicated to advancing breakthrough research, are backed by well-known personalities such as Sergey Brin, Google co-founder and his wife, Anne Wojcicki, co-founder of a personal genomics and biotech company 23andMe; Facebook founder Mark Zuckerberg and his wife, Priscilla Chan; Russian entrepreneur Yuri Milner; and Art Levinson, chairman of Apple and Genentech.
The 11 recipients will each rece...
Source: NCI Benchmarks - March 8, 2013 Category: Cancer & Oncology Authors: Aleea Farrakh Khan Tags: Scientist Spotlight award Source Type: news
